Loading...
Metabolic & Weight Management
Tirzepatide
Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. By activating both incretin pathways, it delivers enhanced metabolic benefits and has shown exceptional results in clinical trials for weight management.
Available Delivery Methods
SubQ Injection
Why Tirzepatide
Key Benefits
- Dual-action mechanism targeting both GIP and GLP-1 receptors
- Demonstrated superior weight loss outcomes in clinical trials
- Improves insulin sensitivity and glycemic control
- Supports reduction in visceral fat
- Once-weekly subcutaneous injection
The Science
How It Works
Tirzepatide activates both GIP and GLP-1 receptors, producing complementary metabolic effects. GLP-1 receptor activation reduces appetite and slows gastric emptying, while GIP receptor activation enhances insulin secretion and may promote fat metabolism, resulting in synergistic weight and metabolic benefits.
Safety & Side Effects
Common side effects include nausea, diarrhea, and decreased appetite, typically improving with gradual dose titration. Not recommended for patients with a history of medullary thyroid carcinoma, MEN 2 syndrome, or severe gastrointestinal disease.
Metabolic & Weight Management
Related Therapies
Interested in Tirzepatide?
Speak with a licensed clinician to find out if Tirzepatide is right for your protocol.
Book a Consultation